Next Article in Journal
Anti-Inflammatory and Antinociceptive Studies of Hydroalcoholic Extract from the Leaves of Phyllanthus brasiliensis (Aubl.) Poir. and Isolation of 5-O-β-d-Glucopyranosyljusticidin B and Six Other Lignans
Next Article in Special Issue
Essential Oils and Their Constituents Targeting the GABAergic System and Sodium Channels as Treatment of Neurological Diseases
Previous Article in Journal
Pursuing Intracellular Pathogens with Hyaluronan. From a ‘Pro-Infection’ Polymer to a Biomaterial for ‘Trojan Horse’ Systems
Previous Article in Special Issue
Coumarin Content, Morphological Variation, and Molecular Phylogenetics of Melilotus
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 4
10.3390/molecules23040940
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Panax Notoginseng Saponins: A Review of Its Mechanisms of Antidepressant or Anxiolytic Effects and Network Analysis on Phytochemistry and Pharmacology

by
Weijie Xie
1,2,3,4,
Xiangbao Meng
1,2,3,4,
Yadong Zhai
1,2,3,4,
Ping Zhou
1,2,3,4,
Tianyuan Ye
1,2,3,4,
Zhen Wang
1,2,3,4,
Guibo Sun
1,2,3,4,* and
Xiaobo Sun
1,2,3,4,*
1
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China
2
Key Laboratory of Bioactive Substances and Resource Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing 100193, China
3
Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Beijing 100193, China
4
Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing 100193, China
*
Authors to whom correspondence should be addressed.
Molecules 2018, 23(4), 940; https://doi.org/10.3390/molecules23040940
Submission received: 14 March 2018 / Revised: 4 April 2018 / Accepted: 6 April 2018 / Published: 17 April 2018
(This article belongs to the Collection Herbal Medicine Research)
Browse Figures
Versions Notes

Abstract

:
Panax notoginseng (Burk) F. H. Chen, as traditional Chinese medicine, has a long history of high clinical value, such as anti-inflammatory, anti-oxidation, inhibition of platelet aggregation, regulation of blood glucose and blood pressure, inhibition of neuronal apoptosis, and neuronal protection, and its main ingredients are Panax notoginseng saponins (PNS). Currently, Panax notoginseng (Burk) F. H. Chen may improve mental function, have anti-insomnia and anti-depression effects, alleviate anxiety, and decrease neural network excitation. However, the underlying effects and the mechanisms of Panax notoginseng (Burk) F. H. Chen and its containing chemical constituents (PNS) on these depression-related or anxiety-related diseases has not been completely established. This review summarized the antidepressant or anxiolytic effects and mechanisms of PNS and analyzed network targets of antidepressant or anxiolytic actions with network pharmacology tools to provide directions and references for further pharmacological studies and new ideas for clinical treatment of nervous system diseases and drug studies and development. The review showed PNS and its components may exert these effects through regulating neurotransmitter mechanism (5-HT, DA, NE), modulation of the gamma-amino butyric acid (GABA) neurotransmission, glutamatergic system, hypo-thalamus-pituitary-adrenal (HPA) axis, brain-derived neurotrophic factor (BDNF), and its intracellular signaling pathways in the central nervous system; and produce neuronal protection by anti-inflammatory, anti-oxidation, or inhibition of neuronal apoptosis, or platelet aggregation and its intracellular signaling pathways. Network target analysis indicated PNS and its components also may have anti-inflammatory and anti-apoptotic effects, which leads to the preservation of brain nerves, and regulate the activity and secretion of nerve cells, exerting anti-depression and anxiolytic effects, which may provide new directions for further in-depth researches of related mechanisms.

1. Introduction

Depression is a chronic and recurrent syndrome of mood disorder with significant and lasting low mood [1,2,3,4]. Clinical depressed patients are characteristic of its disproportionate, emotional depression, being not commensurate with their situation, low self-esteem, and even pessimism, including depressed mood from depression to grief. Some may have suicide attempts or behaviors [5,6]; in severe cases, there may be hallucinations, delusions, and other psychotic symptoms [7]. The pathogenesis and etiology of still remain unknown [8,9,10,11,12,13,14]. However, today’s knowledge proposes multiple neuronal and hormonal systems involved in the pathophysiology of the disease. Current evidence suggests that the occurrence of depression may be related to a reduced secretion of neurotransmitters [15,16,17], such as dopamine (DA), norepinephrine (NE), and serotonin (5-HT), neuronal apoptosis [14,18,19], inflammation [20,21,22,23], intestinal flora [18], and other factors [16,18,24,25]. There are currently four classes of antidepressant drugs and atypical antidepressants [25,26]. However, these drugs have undesirable side effects, with high relapse rates and a long onset of therapeutic action. Therefore, critically important is the development of efficient and safe drugs for the treatment of depression.
Panax notoginsen (Burk) F. H. Chen (Sanqi in Chinese) is a commonly used Chinese medicine, the root of which has been used for the treatment of hemoptysis, hemostatic, and hematoma in China and other Asian countries for its hemostatic and cardiovascular effects for more than several hundred years [26,27,28]. To the best of our knowledge, over 200 chemical constituents have been isolated from Panax notoginseng (Burk) F. H. Chen, but the main ingredients are Panax notoginseng saponins (PNS) [29], being classified into four types: protopanaxadiol, protopanaxatriol, ocotilloltype, and oleanolic acid constituents. There are others reported to be flavonoids, cyclopeptides, saccharides, and inorganic elements [30]. Pharmacological studies have shown that notoginseng and its extracts have many functions, such as anti-inflammatory [16,20,31,32], anti-oxidation, inhibition of platelet aggregation, regulation of blood glucose [27,33,34] and blood pressure [35,36,37], inhibition of neuronal apoptosis [14,38,39], and neuronal protection [30].
Recent studies have found that PNS have good preventive and therapeutic effects on neurological diseases of the brain [28], especially in antidepressant [26,27,28] and anti-anxiety effects [25,28,40]. The preliminary determination was that anti-depressant and anti-anxiety effects may occur by increasing the levels of the brain monoamine neurotransmitters 5-hydroxytryptamine (5-HT) [41,42] and norepinephrine (NE) in the central nervous system. Experiments also have shown that PNS modulates Na+ currents and Ca2+ concentrations, and increases nestin and brain-derived neurotrophic factor (BDNF) [14,19,29,43,44,45,46,47]. Moreover, PNS or single compounds exerted antidepressant-like effects by regulating the release of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, or anti-inflammatory cytokines IL-4 and IL-10 [10,20,29,31,32,36,48,49,50,51,52,53,54,55,56]. Such breakthroughs have been made to determine there are antidepressant effects on estrogen in the human body. Estrogen can act on the PI3K/Akt, MAPK/ERK, mTORC1, and other signaling pathways, and then these pathways are regulated by growth factors that protect neurons and produce estrogen-like effects on synapses. However, the role of PNS or its single compounds in normal function and in disease remains to be not much elucidated.
Therefore, this review summarized the antidepressant or anxiolytic effects and mechanisms of PNS and analyzed network targets of antidepressant or anxiolytic actions with network pharmacology tools, to provide reference for further pharmacological studies and new ideas for clinical treatment of nervous system diseases and drug studies and development.

2. Mechanisms of Antidepression

2.1. Panax Notoginseng Saponins

Modern pharmacological studies have found Panax notoginseng saponins (PNS) have good preventive and therapeutic effects of brain neurological diseases [26,28,57]. Ginsenosides Rg1, Rb1, Re, and notoginsenoside R1, as the representative [26,28,57], showed anti-depressant and anti-anxiety activity [28,31,35,58,59,60,61]. The evaluation methods of antidepressant effects include sucrose preference test (SPF) [62], forced swimming test (FST) [63,64,65], open field test (OFT) [62,64,66], elevated plus-maze (EPM) test, and tail suspension test (TST) [66].
PNS (58.6%) significantly decreased immobility time in the forced swim test with little effect on locomotion in the chronic mild stress model, and significantly improved the level of animal activity and sucrose consumption [67], which may have antidepressant-like effects [45,53,64,65]. Besides this, when PNS was digested by Snail Enzyme to 50%, it produced the best antidepressant effects, and the main active ingredient includes ginsenosides Rb1, Rb2, Rc, and Rb3 [40,60,68,69,70]. These were shown in Table 1.
At present, the antidepressant mechanisms have been partly proved to be that PNS upregulates expression of brain-derived neurotrophic factor (BDNF) by regulating multiple upstream neural signal transduction pathways, including AC/cAMP/PKA [45,71] and mitogen-activated protein kinase channels (TrKB/MAPK/PSK) [37,72]; meanwhile, PNS regulates calmodulin kinase channel (Ca2+/CaM/CaMK), reduces internal concentration of Ca2+ in nerve cells [73], and promotes the release of neurotransmitters 5-HT, NE, and DA [27,32,41,52]. Thereby, PNS exerted its antidepressant-like effect. These are shown in Table 1.
Besides this, both PNS and ginseng total saponin (GTS) have significant antidepressant effects on LPS-induced murine CD-1 mouse models [19,52,53,74] by reducing mRNA levels for IL-1β, IL-6, TNF-α, and indoleamine 2,3-dioxygenase (IDO) in hippocampus [52]. These were shown in Table 1.

2.2. Single Component: Rg1

Among Panax notoginseng saponins, ginsenoside Rg1, Rb1, Rc, and Rb3 are important representative components of PNS antidepressant, belonging to the original ginseng diol type saponins, and the contents of ginsenoside Rb3 and Rc were 17.66% and 9.32%, respectively [25,27,33].
By conducting open field tests (OFT), tail suspension tests (TST), forced swimming tests (FST), or sugar consumption tests, ginsenoside Rg1 showed antidepressant effect in chronic mild stress (CMS)- or chronic unpredictable mild stress (CUMS)-induced animal models of Depression [45,64,67,80]. Ginsenoside Rg1 significantly reversed increase of serum corticosterone induced by CMS, increased the phosphorylation of cAMP response element-binding protein (CREB) in rat cerebral amygdala induced by CUMS, up-regulated expression of BDNF in the hippocampus [32,43,45], and down-regulated serum corticosterone lever [43]. It also regulates the hyperthyroidism of HPA axis in depression, plays a positive role in activating BDNF and protein kinase [43,74], and also improves the neuronal status, and increases the number of neurons and dendritic spine density [32,43,45], producing antidepressant effect.
Moreover, ginsenoside Rg1 could up-regulate the expression of connexin, improve the gap junctional connectivity of astrocytes in the prefrontal cortex, decrease the permeability, increase the ultrastructure, and reduce the depression-like behavior of rats induced by CUMS [79]. As present studies found that Ly6C (hi) blood mononuclear cells can be used as anti-depressant regulatory targets [10], Rg1 selectively suppressed Ly6C hi monocytes recruitment to the inflamed mice brain [10], Rg1 pretreatment on activated THP-1 monocytes retarded their ability to trigger CCL2 secretion from co-cultured U251 MG astrocytes, and CCL2-triggered p38/MAPK and PI3K/Akt activation were blocked by Rg1 [10,81]. Besides this, Rg1 suppressed depression-like behaviors in CUMS model rats by reducing contents of Glu and Asp in hippocampus and increasing GABA and Tau content, exerting antidepressant effects [67].

2.3. Single Component: Rb1

Ginsenoside Rb1 and ginsenoside K, its metabolite, could activate 5-HT2AR, and may also up-regulate the mRNA expression of 5-HT2AR, which showed anti-depressant effects on ovariectomized rat model carried with ovariectomy, whereas the anti-depression effect of Rb1 and ginsenoside K may be reversed by the 5-HT2AR antagonist (ritanserin), which generally indicates that Rb1 has a similar-neurotransmitter of 5-HT activation effect [42]. These were shown in Table 1.

2.4. Single Component: Rb3

Ginsenoside Rb3 had significant anti-immobility effects in mice in the forced swim and tail suspension tests, and reduced the number of escape failures in the learned helplessness procedure by using the forced swimming test, tail suspension test, and learned helplessness procedure. Biochemical variations (i.e., brain-derived neurotrophic factor and the monoamine neurotransmitters 5-hydroxytryptamine, dopamine, and norepinephrine) are mainly involved in Rb3’s antidepressant-like effects [25,27]. Using GABAA receptor agonist muscimol was similar to that of ginsenoside Rb3, which indicated that the activation of the GABAA receptor is correlated with the neuroprotective mechanisms of ginsenoside Rb3 [25,27,86]. These were shown in Table 1.

2.5. Single Component: Rg3

Ginsenoside Rg3 exerted a significant antidepressant effect on LPS-induced mouse model by immunomodulatory and anti-inflammatory effects [19,53,74], which decreased levels of IL-6, TNF-α in plasma and indoleamine-2,3-deoxygenates (IDO) expression in the hippocampus, reduced or inhibited the turnover of the tryptophan-serotonin (5-HT) in the hippocampus, regulated the secretory activity of microglia microglial cells and the transcription of NF-kappa-B in the nucleus, and repaired tryptophan-kynurenine metabolic balance, thereby weakening the depressant-like behavior or symptoms. In addition, Rg3 exerted an anti-depressant effect on chronic social defeat stress (CSDS)-induced mice model, but had no significant effect on animal activity and enhanced BNDF expression [74]. These were shown in Table 1.
Besides this, ginsenoside Rg5 induced antidepressant effect by inhibiting Trk and AchE activity and upregulating BDNF expression in chronic social defeat stress (CSDS)-induced model mice [85]. Ginsenoside Re regulated the central adrenergic system, inhibited tyrosine hydroxylase (TH) expression in the locus coeruleus, blocked the decrease of BDNF in hippocampus, and regulated the secretion of corticosterone in the HPA axis, thus alleviating and regulating the synthesis of depression or anxiety symptoms [44]. These were shown in Table 1.

3. Mechanisms of Antianxiety

At present, representatives of Panax notoginseng (Burk) F. H. Chen, stem and leaf soap components or part of ginsenosides that have been shown to have anxiolytic effects are ginsenoside Rb1, Re, PPD [40,83,87,88], ginsenoside Rh1 [40], and ginsenoside Rg3 [27,53,74,84]. In chronic mild stress (CMS)-induced rats, l-DOPA-induced running behavior in mice or 5-HTP-induced head-twitch tests, PNS decreased immobility time, increased the levels of 5-hydroxytryptamine, dopamine, and noradrenaline, reduced basal [Ca2+]i levels in cultured neurons, which were mediated by modulation of brain monoamine neurotransmitters and intracellular Ca2+ concentration, producing anti-anxiety and antidepressant effect [26,28,89]. These are shown in Table 2.
Ginsenoside Rb1 reduced the anxiety index, increased the risk assessment, reduced grooming behaviors in the EPM test, and increased the total number of line crossings of an open field in single prolonged stress (SPS)-induced model and in model rats of post-traumatic stress disorder (PTSD) by increasing the expression of neuropeptide Y induced by SPS-induced decrease in hypothalamic; increase the expression of tyrosine hydroxylase in locus coeruleus and decrease the mRNA expression of BDNF in hippocampus.
At the same time, ginsenoside Rb1 and Re’s intestinal metabolites PPD and K, ginsenoside Rh1 can increase arm opening time in EPM and reduce the serum levels of adrenone IL-6, and the role of γ-aminobutyrate-A (GABA A) receptor(s) exert anxiolytic effects [27,40]. Pseudoginsenoside-F(11) greatly ameliorated the anxiety-like behaviors induced by MA, shortened MA-induced prolonged latency, decreased the error counts, significant decreases in the contents of dopamine (DA), 3,4-dihydroxyphenacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindoacetic acid (5-HIAA) in the brain of MA-treated mice; and partially, but significantly, a antagonize MA-induced decreases of DA [90]. Besides, Ginsenoside Rg3, Rh2, Rg1 and Ro significantly increased both the frequency and duration of open arm entries, indicating that ginsenoside Rb1 is one of the active anxiolytic components [84]. These were shown in Table 2.

4. Network Target Analysis

Based on reported researches of each component above, including ginsenoside Rg1, Rg3, Rg5, Rb1, Rb3, Re, Rh1, Rh2, Ro, pseudoginsenoside-F(11), ginsenoside K, and notoginsenoside R1, the structures and target properties of 12 active ingredients among them was obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/), shown as Table 3; then network targets of antidepressant, anxiolytic actions, or other pharmacological effects were analyzed with network pharmacology tools. In the present work, an integrated in silico approach was introduced to identify the target proteins for the active ingredients of Panax notoginseng (Burk) F. H. Chen (Table 3). Predictive models were used, including STITCH (http://stitch.embl.de/) and Swiss Target Prediction (http://www.swisstargetprediction.ch/), and databases were mined including Herbal Ingredients’ Targets database (http://lifecenter.sgst.cn/hit/) [93,94]. Finally, targets related to antidepressant or anxiolytic effects and other effects were determined, interacting with the selected 12 active ingredients of Panax notoginseng (Burk) F. H. Chen (Table 4).
Main predicted network targets of Panax notoginseng (Burk) F. H. Chen were shown in Table 4 and Figure 1. Twenty-six targets were identified for 12 active ingredients of Panax notoginseng (Burk) F. H. Chen with 87 interactions. The more link lines between compounds and predicted protein targets, the greater the linear density, indicating that they are more likely to interact, but specific experiments are needed to confirm. This is shown in Figure 1.
Based on the scores (Table 4), multiple therapeutic targets concerning central nervous system were mediated by the active ingredients of Panax notoginseng (Burk) F. H. Chen, such as BAK1, BCL2, BCL2A1, JUN, MAPK8, AKT1, NFKB1, TP53, and APAF1. Most of these targets are mainly involved in apoptosis and inflammation of vascular and central neural systems. Figure 1 and Figure 2 show that BCL2-A1, BCL2, NF-kappa-B, and TP53 was predicted to have strong association actions of compound and predicted target network of Panax notoginseng (Burk) F. H. Chen, indicating that Notoginseng saponins may exert anti-depression and anti-anxiety effects through inflammatory regulation and anti-apoptotic pathway.
BCL2 suppresses apoptosis in a variety of cell systems, including neural cells and factor-dependent lymphohematopoietic, and regulates cell death by controlling the mitochondrial membrane permeability by binding to the apoptosis-activating factor (APAF-1). NF-kappa-B is a pleiotropic transcription factor present in almost all cell types, and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes, such as inflammation, immunity, differentiation, cell growth, tumorigenesis, and apoptosis. TP53 acts as a tumor suppressor in many tumor types, and induces growth arrest or apoptosis depending on the physiological circumstances and cell type, involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. These indicate that PNS may have anti-inflammatory and anti-apoptotic effects, which leads to the preservation of brain nerves, and regulate the activity and secretion of nerve cells, exerting anti-depression and anxiolytic effects, which may provide new directions for further in-depth researches of related mechanisms.

5. Conclusions

Depression is becoming the world’s fourth-largest disease, and may become the second-largest disease in 2020, second only to cardiac disease. Antidepressants can be divided into four categories: tricyclic, tetracyclic, monoamine oxidase inhibitors, and other new antidepressants, and sometimes can cause addiction or undesirable side effects. Therefore, new drugs or treatment methods are required. Future studies should consider investigating alternatives to conventional drugs or Chinese medicinal plants. These have been used for more than a thousand years with generally carry a low risk of negative side effects. Panax notoginseng (Burk) F. H. Chen, as traditional Chinese medicine has a long history of high clinical value, such as anti-inflammatory [16,20,31,32], anti-oxidation, inhibition of platelet aggregation, regulation of blood glucose [27,33,34] and blood pressure [35,36,37], inhibition of neuronal apoptosis [14,38,39], and neuronal protection. Currently, Panax notoginseng (Burk) F. H. Chen may improve mental function, have anti-insomnia and anti-depression effects, alleviate anxiety, and decrease neural network excitation [25,26].
As outlined above, we have confirmed that PNS, ginsenoside Rg1, ginsenoside Rb1, ginsenosidenRg3, ginsenoside Rh2, ginsenoside Rg5, K, and ginsenoside Re have antidepressant or anxiolytic effects, and ginsenoside Rh1and pseudoginsenoside-F(11) have anxiolytic effects. These components may exert these effects through regulating neurotransmitter mechanism (5-HT, DA, NE), modulation of the gamma-amino butyric acid (GABA) neurotransmission, glutamatergic system, hypo-thalamus-pituitary-adrenal (HPA) axis, brain-derived neurotrophic factor (BDNF), and its intracellular signaling pathways in the central nervous system; and produce neuronal protection by anti-inflammatory, anti-oxidation, inhibition of neuronal apoptosis, or platelet aggregation and its intracellular signaling pathways.
Although, among them, some compounds have been only proved to have antidepressant or anxiolytic effects in GTS [95], the main chemical composition of Panax notoginseng (Burk) F. H. Chen is similar to that of ginseng; at present, less researches have been shown on the role of Panax notoginseng (Burk) F. H. Chen and chemical composition in anti-anxiety and anti-depression. Therefore, as a potential new drug, a systematic and in-depth study of the effects and its molecular mechanisms of anti-anxiety and anti-depression of Panax notoginseng (Burk) F. H. Chen is needed.
Further work on elucidation of the structure–function relationship among saponins, understanding of multi-target network pharmacology of Panax notoginseng (Burk) F. H. Chen with Network Pharmacology tools, as well as developing its new clinical usage and comprehensive utilize will enhance the therapeutic potentials of Panax notoginseng (Burk) F. H. Chen. A clearer understanding of the mechanisms underlying the effects of Panax notoginseng (Burk) F. H. Chen on human cytokine/metabolic systems and on stress-induced hormonal changes could facilitate the development of a wide range of treatments for patients with psychological and physical diseases.

Acknowledgments

This work was supported by the Major Scientific and Technological Special Project for “Significant New Drugs Formulation” (No. 2017ZX09101003-009), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. 2016-I2M-1-012), the CAMS Initiative for Innovative Medicine (No. CAMS-I2M-1-010), the Special Research Project for TCM (No. 201507004), the National Natural Science Foundation of China (No. 81503290), and The National Natural Science Foundation of China (NO. 81773938).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Dean, J.; Keshavan, M. The neurobiology of depression: An integrated view. Asian J. Psychiatry 2017, 27, 101–111. [Google Scholar] [CrossRef] [PubMed]
  2. Dell’Osso, L.; Carmassi, C.; Mucci, F.; Marazziti, D. Depression, Serotonin and Tryptophan. Curr. Pharm. Des. 2016, 22, 949–954. [Google Scholar] [CrossRef] [PubMed]
  3. Dunn, E.C.; Brown, R.C.; Dai, Y.; Rosand, J.; Nugent, N.R.; Amstadter, A.B.; Smoller, J.W. Genetic determinants of depression: Recent findings and future directions. Harv. Rev. Psychiatry 2015, 23, 1–18. [Google Scholar] [CrossRef] [PubMed]
  4. Hashmi, A.M.; Butt, Z.; Umair, M. Is depression an inflammatory condition? A review of available evidence. J. Pak. Med. Assoc. 2013, 63, 899–906. [Google Scholar] [PubMed]
  5. Catena-Dell’Osso, M.; Caserta, A.; Baroni, S.; Nisita, C.; Marazziti, D. The relationship between epilepsy and depression: An update. Curr. Med. Chem. 2013, 20, 2861–2867. [Google Scholar] [PubMed]
  6. Limon, A.; Mamdani, F.; Hjelm, B.E.; Vawter, M.P.; Sequeira, A. Targets of polyamine dysregulation in major depression and suicide: Activity-dependent feedback, excitability, and neurotransmission. Neurosci. Biobehav. Rev. 2016, 66, 80–91. [Google Scholar] [CrossRef] [PubMed]
  7. Novais, F.; Starkstein, S. Phenomenology of Depression in Alzheimer’s Disease. J. Alzheimers Dis. 2015, 47, 845–855. [Google Scholar] [CrossRef] [PubMed]
  8. Stepanichev, M.; Dygalo, N.N.; Grigoryan, G.; Shishkina, G.T.; Gulyaeva, N. Rodent models of depression: Neurotrophic and neuroinflammatory biomarkers. BioMed Res. Int. 2014, 2014, 932757. [Google Scholar] [CrossRef] [PubMed]
  9. Uchida, S.; Yamagata, H.; Seki, T.; Watanabe, Y. Epigenetic mechanisms of major depression: Targeting neuronal plasticity. Psychiatry Clin. Neurosci. 2017. [Google Scholar] [CrossRef] [PubMed]
  10. Zheng, X.; Ma, S.; Kang, A.; Wu, M.; Wang, L.; Wang, Q.; Wang, G.; Hao, H. Chemical dampening of Ly6C(hi) monocytes in the periphery produces anti-depressant effects in mice. Sci. Rep. 2016, 6, 19406. [Google Scholar] [CrossRef] [PubMed]
  11. Zong, S.; Hoffmann, C.; Mane-Damas, M.; Molenaar, P.; Losen, M.; Martinez, P. Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression? Front. Immunol. 2017, 8, 752. [Google Scholar] [CrossRef] [PubMed]
  12. Chi, S.; Yu, J.T.; Tan, M.S.; Tan, L. Depression in Alzheimer’s disease: Epidemiology, mechanisms, and management. J. Alzheimers Dis. 2014, 42, 739–755. [Google Scholar] [PubMed]
  13. Flaster, M.; Sharma, A.; Rao, M. Poststroke depression: A review emphasizing the role of prophylactic treatment and synergy with treatment for motor recovery. Top. Stroke Rehabil. 2013, 20, 139–150. [Google Scholar] [CrossRef] [PubMed]
  14. Li, W.; Ling, S.; Yang, Y.; Hu, Z.; Davies, H.; Fang, M. Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuro Endocrinol. Lett. 2014, 35, 104–109. [Google Scholar] [PubMed]
  15. Benson, C.; Mifflin, K.; Kerr, B.; Jesudasan, S.J.; Dursun, S.; Baker, G. Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression. Mod. Trends Pharmacopsychiatry 2015, 30, 67–79. [Google Scholar] [PubMed]
  16. Jeon, S.W.; Kim, Y.K. Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J. Psychiatry 2016, 6, 283–293. [Google Scholar] [CrossRef] [PubMed]
  17. Oakes, P.; Loukas, M.; Oskouian, R.J.; Tubbs, R.S. The neuroanatomy of depression: A review. Clin. Anat. 2017, 30, 44–49. [Google Scholar] [CrossRef] [PubMed]
  18. Lin, F.B.; Hou, D.R.; Tang, Q.P. Research progress of depression and the application of esketamine. J. South. Med. Univ. 2016, 37, 567. [Google Scholar]
  19. Zhang, H.; Zhou, Z.; Chen, Z.; Zhong, Z.; Li, Z. Ginsenoside Rg3 exerts anti-depressive effect on an NMDA-treated cell model and a chronic mild stress animal model. J. Pharmacol. Sci. 2017, 134, 45–54. [Google Scholar] [CrossRef] [PubMed]
  20. Allison, D.J.; Ditor, D.S. The common inflammatory etiology of depression and cognitive impairment: A therapeutic target. J. Neuroinflamm. 2014, 11, 151. [Google Scholar] [CrossRef] [PubMed]
  21. Anderson, G.; Maes, M. Neurodegeneration in Parkinson’s disease: Interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol. Neurobiol. 2014, 49, 771–783. [Google Scholar] [CrossRef] [PubMed]
  22. Anderson, G.; Maes, M. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson’s disease. CNS Neurol. Disord. Drug Targets 2014, 13, 137–149. [Google Scholar] [CrossRef]
  23. Anderson, G.; Seo, M.; Berk, M.; Carvalho, A.F.; Maes, M. Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. Curr. Pharm. Des. 2016, 22, 6142–6151. [Google Scholar] [CrossRef] [PubMed]
  24. Braga, J.; Campar, A. Biological causes of depression in Systemic Lupus Erythematosus. Acta Reumatol. Port. 2014, 39, 218–226. [Google Scholar] [PubMed]
  25. Cui, J.; Jiang, L.; Xiang, H. Ginsenoside Rb3 exerts antidepressant-like effects in several animal models. J. Psychopharmacol. 2012, 26, 697–713. [Google Scholar] [CrossRef] [PubMed]
  26. Xiang, H.; Liu, Y.; Zhang, B.; Huang, J.; Li, Y.; Yang, B.; Huang, Z.; Xiang, F.; Zhang, H. The antidepressant effects and mechanism of action of total saponins from the caudexes and leaves of Panax notoginseng in animal models of depression. Phytomedicine 2011, 18, 731–738. [Google Scholar] [CrossRef] [PubMed]
  27. Zhang, H.; Li, Z.; Zhou, Z.; Yang, H.; Zhong, Z.; Lou, C. Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, K, and 20(S)-protopanaxadiol in mice models of despair. Pharmacol. Biochem. Behav. 2016, 140, 17–26. [Google Scholar] [CrossRef] [PubMed]
  28. Su, P.; Wang, L.; Du, S.J.; Xin, W.F.; Zhang, W.S. Advance in studies of Panax notoginseng saponins on pharmacological mechanism of nervous system disease. Zhongguo Zhong Yao Za Zhi 2014, 39, 4516–4521. [Google Scholar] [PubMed]
  29. Bahramsoltani, R.; Farzaei, M.H.; Farahani, M.S.; Rahimi, R. Phytochemical constituents as future antidepressants: A comprehensive review. Rev. Neurosci. 2015, 26, 699–719. [Google Scholar] [CrossRef] [PubMed]
  30. Wang, T.; Guo, R.; Zhou, G.; Zhou, X.; Kou, Z.; Sui, F.; Li, C.; Tang, L.; Wang, Z. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: A review. J. Ethnopharmacol. 2016, 188, 234–258. [Google Scholar] [CrossRef] [PubMed]
  31. Zhang, J.; Ding, L.; Wang, B.; Ren, G.; Sun, A.; Deng, C.; Wei, X.; Mani, S.; Wang, Z.; Dou, W. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. J. Pharmacol. Exp. Ther. 2015, 352, 315–324. [Google Scholar] [CrossRef] [PubMed]
  32. Zheng, X.; Liang, Y.; Kang, A.; Ma, S.J.; Xing, L.; Zhou, Y.Y.; Dai, C.; Xie, H.; Xie, L.; Wang, G.J.; et al. Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats. Neuroscience 2014, 256, 210–222. [Google Scholar] [CrossRef] [PubMed]
  33. Kim, N.H.; Kim, K.Y.; Jeong, H.J.; Kim, H.M. Antidepressant-like effect of altered Korean red ginseng in mice. Behav. Med. 2011, 37, 42–46. [Google Scholar] [CrossRef] [PubMed]
  34. Xie, T.; Zhou, X.P.; Lin, L.L.; Xu, J.Y.; Shen, C.S.; Feng, Z.; Zhou, L.L.; Shan, J.J. Metabolomics analysis of Tripterygium wilfordii formulation based on theory of detoxicity compatibility. Zhongguo Zhong Yao Za Zhi 2016, 41, 1124–1129. [Google Scholar] [PubMed]
  35. Pang, H.H.; Li, M.Y.; Wang, Y.; Tang, M.K.; Ma, C.H.; Huang, J.M. Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule. J. Zhejiang Univ. Sci. B 2017, 18, 343–352. [Google Scholar] [CrossRef] [PubMed]
  36. Tian, Z.; Pang, H.; Du, S.; Lu, Y.; Zhang, L.; Wu, H.; Guo, S.; Wang, M.; Zhang, Q. Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats. J. Chromatogr. B 2017, 1040, 136–143. [Google Scholar] [CrossRef] [PubMed]
  37. Zhao, S.; Zheng, M.X.; Chen, H.E.; Wu, C.Y.; Wang, W.T. Effect of panax notoginseng saponins injection on the p38MAPK pathway in lung tissue in a rat model of hypoxic pulmonary hypertension. Chin. J. Integr. Med. 2015, 21, 147–151. [Google Scholar] [CrossRef] [PubMed]
  38. Hou, Q.L.; Wang, Y.; Li, Y.B.; Hu, X.L.; Wang, S.L. Protective effect of notoginsenoside R1 on neuron injury induced by OGD/R through ATF6/Akt signaling pathway. Zhongguo Zhong Yao Za Zhi 2017, 42, 1167–1174. [Google Scholar] [PubMed]
  39. Yang, X.; Yang, S.; Hong, C.; Yu, W.; Guonian, W. Panax Notoginseng Saponins attenuates sevofluraneinduced nerve cell injury by modulating AKT signaling pathway. Mol. Med. Rep. 2017, 16, 7829–7834. [Google Scholar] [CrossRef] [PubMed]
  40. Oh, H.A.; Kim, D.-E.; Choi, H.J.; Kim, N.J.; Kim, D.-H. Anti-stress Effects of 20(S)-Protopanaxadiol and 20(S)-Protopanaxatriol in Immobilized Mice. Biol. Pharm. Bull. 2015, 38, 331–335. [Google Scholar] [CrossRef] [PubMed]
  41. Albert, P.R.; Fiori, L.M. Transcriptional dys-regulation in anxiety and major depression: 5-HT1A gene promoter architecture as a therapeutic opportunity. Curr. Pharm Des. 2014, 20, 3738–3750. [Google Scholar] [CrossRef] [PubMed]
  42. Liu, M.Y.; Zhang, L.J.; Liu, M.C. Effect of ginsenoside pre-treatment on 5-hydroxytryptamine system in SD rats with myocardial infarction and depression. Zhonghua Nei Ke Za Zhi 2016, 55, 700–704. [Google Scholar] [PubMed]
  43. Jiang, B.; Xiong, Z.; Yang, J.; Wang, W.; Wang, Y.; Hu, Z.L.; Wang, F.; Chen, J.G. Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus. Br. J. Pharmacol. 2012, 166, 1872–1887. [Google Scholar] [CrossRef] [PubMed]
  44. Lee, B.; Shim, I.; Lee, H.; Hahm, D.H. Effect of ginsenoside Re on depression- and anxiety-like behaviors and cognition memory deficit induced by repeated immobilization in rats. J. Microbiol. Biotechnol. 2012, 22, 708–720. [Google Scholar] [CrossRef] [PubMed]
  45. Liu, Z.; Qi, Y.; Cheng, Z.; Zhu, X.; Fan, C.; Yu, S.Y. The effects of ginsenoside Rg1 on chronic stress induced depression-like behaviors, BDNF expression and the phosphorylation of PKA and CREB in rats. Neuroscience 2016, 322, 358–369. [Google Scholar] [CrossRef] [PubMed]
  46. Si, Y.; Zhu, J.; Huang, X.; Zhu, P.; Xie, C. Effects of Panax notoginseng saponins on proliferation and differentiation of rat embryonic cortical neural stem cells. J. Chin. Med. Assoc. 2016, 79, 256–263. [Google Scholar] [CrossRef] [PubMed]
  47. Zhao, M.; Chen, L.; Yang, J.; Han, D.; Fang, D.; Qiu, X.; Yang, X.; Qiao, Z.; Ma, J.; Wang, L.; et al. BDNF Val66Met polymorphism, life stress and depression: A meta-analysis of gene-environment interaction. J. Affect. Disord. 2017, 227, 226–235. [Google Scholar] [CrossRef] [PubMed]
  48. Anderson, G.; Berk, M.; Dean, O.; Moylan, S.; Maes, M. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 2014, 28, 1–10. [Google Scholar] [CrossRef] [PubMed]
  49. Anderson, G.; Maes, M.; Berk, M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog. Neuropsychopharm. Biol. Psychiatry 2013, 42, 101–114. [Google Scholar] [CrossRef] [PubMed]
  50. Choi, J.G.; Jin, Y.H.; Lee, H.; Oh, T.W.; Yim, N.H.; Cho, W.K.; Ma, J.Y. Protective Effect of Panax notoginseng Root Water Extract against Influenza A Virus Infection by Enhancing Antiviral Interferon-Mediated Immune Responses and Natural Killer Cell Activity. Front. Immunol. 2017, 8, 1542. [Google Scholar] [CrossRef] [PubMed]
  51. Han, J.Y.; Li, Q.; Ma, Z.Z.; Fan, J.Y. Effects and mechanisms of compound Chinese medicine and major ingredients on microcirculatory dysfunction and organ injury induced by ischemia/reperfusion. Pharmacol. Ther. 2017, 177, 146–173. [Google Scholar] [CrossRef] [PubMed]
  52. Kang, A.; Hao, H.; Zheng, X.; Liang, Y.; Xie, Y.; Xie, T.; Dai, C.; Zhao, Q.; Wu, X.; Xie, L.; et al. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J. Neuroinflamm. 2011, 8, 100. [Google Scholar] [CrossRef] [PubMed]
  53. Kang, A.; Xie, T.; Zhu, D.; Shan, J.; Di, L.; Zheng, X. Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice. J. Agric. Food Chem. 2017, 65, 6861–6869. [Google Scholar] [CrossRef] [PubMed]
  54. Pan, L.; Zhang, Y.; Lu, J.; Geng, Z.; Jia, L.; Rong, X.; Wang, Z.; Zhao, Q.; Wu, R.; Chu, M.; et al. Panax Notoginseng Saponins Ameliorates Coxsackievirus B3-Induced Myocarditis by Activating the Cystathionine-gamma-Lyase/Hydrogen Sulfide Pathway. J. Cardiovasc. Transl. Res. 2015, 8, 536–544. [Google Scholar] [CrossRef] [PubMed]
  55. Wang, J.; Lu, L.; Wang, Y.; Wu, Y.; Han, J.; Wang, W.; Li, C.; Tu, P. Qishenyiqi Dropping Pill attenuates myocardial fibrosis in rats by inhibiting RAAS-mediated arachidonic acid inflammation. J. Ethnopharmacol. 2015, 176, 375–384. [Google Scholar] [CrossRef] [PubMed]
  56. Wenxi, D.; Shufang, D.; Xiaoling, Y.; Liming, Y. Panax notoginseng saponins suppress radiation-induced osteoporosis by regulating bone formation and resorption. Phytomedicine 2015, 22, 813–819. [Google Scholar] [CrossRef] [PubMed]
  57. Wu, J.X.; Chen, J.X. Negative chronotropic and inotropic effects of Panax notoginseng saponins. Zhongguo Yao Li Xue Bao 1988, 9, 409–412. [Google Scholar] [PubMed]
  58. Ge, Z.R.; Xu, M.C.; Huang, Y.U.; Zhang, C.J.; Lin, J.E.; Ruan, C.W. Cardioprotective effect of notoginsenoside R1 in a rabbit lung remote ischemic postconditioning model via activation of the TGF-beta1/TAK1 signaling pathway. Exp. Ther. Med. 2016, 11, 2341–2348. [Google Scholar] [CrossRef] [PubMed]
  59. Wang, T.; Wan, D.; Shao, L.; Dai, J.; Jiang, C. Notoginsenoside R1 stimulates osteogenic function in primary osteoblasts via estrogen receptor signaling. Biochem. Biophys. Res. Commun. 2015, 466, 232–239. [Google Scholar] [CrossRef] [PubMed]
  60. Wang, Y.; Ren, Y.; Xing, L.; Dai, X.; Liu, S.; Yu, B.; Wang, Y. Endothelium-dependent vasodilation effects of Panax notoginseng and its main components are mediated by nitric oxide and cyclooxygenase pathways. Exp. Ther. Med. 2016, 12, 3998–4006. [Google Scholar] [CrossRef] [PubMed]
  61. Xu, Y.; Lin, L.; Tang, L.; Zheng, M.; Ma, Y.; Huang, L.; Meng, W.; Wang, W. Notoginsenoside R1 attenuates hypoxia and hypercapnia-induced vasoconstriction in isolated rat pulmonary arterial rings by reducing the expression of ERK. Am. J. Chin. Med. 2014, 42, 799–816. [Google Scholar] [CrossRef] [PubMed]
  62. Luo, J.; Min, S.; Wei, K.; Zhang, J.; Liu, Y. Propofol interacts with stimulus intensities of electroconvulsive shock to regulate behavior and hippocampal BDNF in a rat model of depression. Psychiatry Res. 2012, 198, 300–306. [Google Scholar] [CrossRef] [PubMed]
  63. Gazal, M.; Ortmann, C.F.; Martins, F.A.; Streck, E.L.; Quevedo, J.; de Campos, A.M.; Stefanello, F.M.; Kaster, M.P.; Ghisleni, G.; Reginatto, F.H.; et al. Antidepressant-like effects of aqueous extract from Cecropia pachystachya leaves in a mouse model of chronic unpredictable stress. Brain Res. Bull. 2014, 108, 10–17. [Google Scholar] [CrossRef] [PubMed]
  64. Pechlivanova, D.; Tchekalarova, J.; Nikolov, R.; Yakimova, K. Dose-dependent effects of caffeine on behavior and thermoregulation in a chronic unpredictable stress model of depression in rats. Behav. Brain Res. 2010, 209, 205–211. [Google Scholar] [CrossRef] [PubMed]
  65. Taksande, B.G.; Faldu, D.S.; Dixit, M.P.; Sakaria, J.N.; Aglawe, M.M.; Umekar, M.J.; Kotagale, N.R. Agmatine attenuates chronic unpredictable mild stress induced behavioral alteration in mice. Eur. J. Pharmacol. 2013, 720, 115–120. [Google Scholar] [CrossRef] [PubMed]
  66. Shi, M.; Wang, J.Y.; Luo, F. Depression shows divergent effects on evoked and spontaneous pain behaviors in rats. J. Pain 2010, 11, 219–229. [Google Scholar] [CrossRef] [PubMed]
  67. Wu, H.F.; Zhu, C.H.; Guo, J.Y. Effect of ginsenoside Rg1 on behaviors and hippocampal amino acids in depressive-like rats. Zhongguo Zhong Yao Za Zhi 2012, 37, 3117–3121. [Google Scholar] [PubMed]
  68. Carr, M.N.; Bekku, N.; Yoshimura, H. Identification of anxiolytic ingredients in ginseng root using the elevated plus-maze test in mice. Eur. J. Pharmacol. 2006, 531, 160–165. [Google Scholar] [CrossRef] [PubMed]
  69. Cha, H.Y.; Park, J.H.; Hong, J.T.; Yoo, H.S.; Song, S.; Hwang, B.Y.; Eun, J.S.; Oh, K.W. Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice. Biol. Pharm. Bull. 2005, 28, 1621–1625. [Google Scholar] [CrossRef] [PubMed]
  70. Huang, X.P.; Ding, H.; Lu, J.D.; Tang, Y.H.; Deng, B.X.; Deng, C.Q. Effects of the Combination of the Main Active Components of Astragalus and Panax notoginseng on Inflammation and Apoptosis of Nerve Cell after Cerebral Ischemia-Reperfusion. Am. J. Chin. Med. 2015, 43, 1419–1438. [Google Scholar] [CrossRef] [PubMed]
  71. Huang, X.P.; Ding, H.; Wang, B.; Qiu, Y.Y.; Tang, Y.H.; Zeng, R.; Deng, C.Q. Effects of the main active components combinations of Astragalus and Panax notoginseng on energy metabolism in brain tissues after cerebral ischemia-reperfusion in mice. Pharmacogn. Mag. 2015, 11, 732–739. [Google Scholar] [PubMed]
  72. Qi, H.; Huang, Y.; Yang, Y.; Dou, G.; Wan, F.; Zhang, W.; Yang, H.; Wang, L.; Wu, C.; Li, L. Anti-platelet activity of panaxatriol saponins is mediated by suppression of intracellular calcium mobilization and ERK2/p38 activation. BMC Complement. Altern. Med. 2016, 16, 174. [Google Scholar] [CrossRef] [PubMed]
  73. Li, Q.; Guan, Y.; Ma, H.J.; Guo, Z.; He, R.R.; Zhang, Y. Influences of Panax notoginsenosid on spontaneous contraction of small intestine smooth muscle of rabbits in vitro. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010, 26, 117–120. [Google Scholar] [PubMed]
  74. You, Z.; Yao, Q.; Shen, J.; Gu, Z.; Xu, H.; Wu, Z.; Chen, C.; Li, L. Antidepressant-like effects of ginsenoside Rg3 in mice via activation of the hippocampal BDNF signaling cascade. J. Nat. Med. 2017, 71, 367–379. [Google Scholar] [CrossRef] [PubMed]
  75. Leff-Gelman, P.; Mancilla-Herrera, I.; Flores-Ramos, M.; Cruz-Fuentes, C.; Reyes-Grajeda, J.P.; Garcia-Cuetara Mdel, P.; Bugnot-Perez, M.D.; Pulido-Ascencio, D.E. The Immune System and the Role of Inflammation in Perinatal Depression. Neurosci. Bull. 2016, 32, 398–420. [Google Scholar] [CrossRef] [PubMed]
  76. Wang, J.; Li, D.; Hou, J.; Lei, H. Protective effects of geniposide and ginsenoside Rg1 combination treatment on rats following cerebral ischemia are mediated via microglial microRNA1555p inhibition. Mol. Med. Rep. 2018, 17, 3186–3193. [Google Scholar] [PubMed]
  77. Xu, C.; Teng, J.; Chen, W.; Ge, Q.; Yang, Z.; Yu, C.; Yang, Z.; Jia, W. 20(S)-protopanaxadiol, an active ginseng metabolite, exhibits strong antidepressant-like effects in animal tests. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 1402–1411. [Google Scholar] [CrossRef] [PubMed]
  78. Yin, S.; Cheng, Y.; Li, T.; Dong, M.; Zhao, H.; Liu, G. Effects of notoginsenoside R1 on CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 activities in rats by cocktail probe drugs. Pharm. Biol. 2016, 54, 231–236. [Google Scholar] [CrossRef] [PubMed]
  79. Chen, W.; Dang, Y.; Zhu, C. Simultaneous determination of three major bioactive saponins of Panax notoginseng using liquid chromatography-tandem mass spectrometry and a pharmacokinetic study. Chin. Med. 2010, 5, 12. [Google Scholar] [CrossRef] [PubMed]
  80. Ducottet, C.; Aubert, A.; Belzung, C. Susceptibility to subchronic unpredictable stress is related to individual reactivity to threat stimuli in mice. Behav. Brain Res. 2004, 155, 291–299. [Google Scholar] [CrossRef] [PubMed]
  81. Zhang, C.; Li, C.; Chen, S.; Li, Z.; Ma, L.; Jia, X.; Wang, K.; Bao, J.; Liang, Y.; Chen, M.; et al. Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K/AKT/mTOR and AMPK/SIRT1/FOXO3 pathways. Sci. Rep. 2017, 7, 41082. [Google Scholar] [CrossRef] [PubMed]
  82. Shi, X.; Yu, W.; Yang, T.; Liu, W.; Zhao, Y.; Sun, Y.; Chai, L.; Gao, Y.; Dong, B.; Zhu, L. Panax notoginseng saponins provide neuroprotection by regulating NgR1/RhoA/ROCK2 pathway expression, in vitro and in vivo. J. Ethnopharmacol. 2016, 190, 301–312. [Google Scholar] [CrossRef] [PubMed]
  83. Yamada, N.; Araki, H.; Yoshimura, H. Identification of antidepressant-like ingredients in ginseng root (Panax ginseng C.A. Meyer) using a menopausal depressive-like state in female mice: participation of 5-HT2A receptors. Psychopharmacology 2011, 216, 589–599. [Google Scholar] [CrossRef] [PubMed]
  84. Kim, T.W.; Choi, H.J.; Kim, N.J.; Kim, D.H. Anxiolytic-like effects of ginsenosides Rg3 and Rh2 from red ginseng in the elevated plus-maze model. Planta Med. 2009, 75, 836–839. [Google Scholar] [CrossRef] [PubMed]
  85. Xu, D.; Wang, C.; Zhao, W.; Gao, S.; Cui, Z. Antidepressant-like effects of ginsenoside Rg5 in mice: Involving of hippocampus BDNF signaling pathway. Neurosci. Lett. 2017, 645, 97–105. [Google Scholar] [CrossRef] [PubMed]
  86. Jiang, S.; Miao, B.; Song, X.; Jiang, Z. Inactivation of GABA(A) receptor reduces ginsenoside Rb3 neuroprotection in mouse hippocampal slices after oxygen-glucose deprivation. J. Ethnopharmacol. 2011, 133, 914–916. [Google Scholar] [CrossRef] [PubMed]
  87. Cheong, J.H.; Song, M.-R.; Lee, Y.S.; Her, Y.; Yim, D.S.; Ko, H.S.; Ryu, Y.S.; Choi, E.J.; Yoon, S.Y.; Choi, J.H. Anxiolytic and Antidepressant Activities of Ginsenoside Rb1. Biomol. Ther. 2007, 15, 27–33. [Google Scholar]
  88. Churchill, J.D.; Gerson, J.L.; Hinton, K.A.; Mifek, J.L.; Walter, M.J.; Winslow, C.L.; Deyo, R.A. The nootropic properties of ginseng saponin Rb1 are linked to effects on anxiety. Integr. Physiol. Behav. Sci. 2002, 37, 178–187. [Google Scholar] [CrossRef] [PubMed]
  89. Wang, Z.J.; Song, L.; Guo, L.C.; Yin, M.; Sun, Y.N. Induction of differentiation by panaxydol in human hepatocarcinoma SMMC-7721 cells via cAMP and MAP kinase dependent mechanism. Yakugaku Zasshi 2011, 131, 993–1000. [Google Scholar] [CrossRef] [PubMed]
  90. Wu, C.F.; Liu, Y.L.; Song, M.; Liu, W.; Wang, J.H.; Li, X.; Yang, J.Y. Protective effects of pseudoginsenoside-F11 on methamphetamine-induced neurotoxicity in mice. Pharmacol. Biochem. Behav. 2003, 76, 103–109. [Google Scholar] [CrossRef]
  91. Lee, B.; Sur, B.; Cho, S.G.; Yeom, M.; Shim, I.; Lee, H.; Hahm, D.H. Ginsenoside Rb1 rescues anxiety-like responses in a rat model of post-traumatic stress disorder. J. Nat. Med. 2016, 70, 133–144. [Google Scholar] [CrossRef] [PubMed]
  92. Lee, B.-H.; Kim, H.-J.; Chung, L.; Nah, S.-Y. Ginsenoside Rg(3) regulates GABA(A) receptor channel activity: Involvement of interaction with the gamma(2) subunit. Eur. J. Pharmacol. 2013, 705, 119–125. [Google Scholar] [CrossRef] [PubMed]
  93. Yue, S.-J.; Xin, L.-T.; Fan, Y.-C.; Li, S.-J.; Tang, Y.-P.; Duan, J.-A.; Guan, H.-S.; Wang, C.-Y. Herb pair Danggui-Honghua: Mechanisms underlying blood stasis syndrome by system pharmacology approach. Sci. Rep. 2017, 7, 40318. [Google Scholar] [CrossRef] [PubMed]
  94. Li, J.; Zhao, P.; Li, Y.; Tian, Y.; Wang, Y. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease. Sci. Rep. 2015, 5, 1–15. [Google Scholar] [CrossRef] [PubMed]
  95. Lee, S.; Rhee, D.K. Effects of ginseng on stress-related depression, anxiety, and the hypothalamic-pituitary-adrenal axis. J. Ginseng Res. 2017, 41, 589–594. [Google Scholar] [CrossRef] [PubMed]
Molecules 23 00940 g001 550
Figure 1. Compound-target network of Panax notoginseng (Burk) F. H. Chen. Edges represent protein-protein associations; protein–protein interactions are shown in grey, chemical–protein interactions in green, and interactions between chemicals in red; stronger associations are represented by thicker lines. Small nodes: protein of unknown 3D structure; large nodes: some 3D structure is known or predicted; colored nodes: query proteins and first shell of interactors; white nodes: second shell of interactors. The chemical groups and structures in the gray rectangles, such as carbon dioxide, oxygen, and HO-, suggest functional links and predictions for specific actions on with potentially acting protein targets and combined scores of predicted interactions presented by analysing the Experimental/Biochemical Data, Association in Curated Databases and Co-Mentioned in PubMed Abstracts, which illustrated the possibility of interaction between compounds and potential protein targets. Associations are meant to be specific and meaningful, i.e., Proteins jointly contribute to a shared function; this does not necessarily mean they are physically binding each other. Predicted models were constructed by STITCH, Swiss Target Prediction, and Herbal Ingredients’ Targets database.
Figure 1. Compound-target network of Panax notoginseng (Burk) F. H. Chen. Edges represent protein-protein associations; protein–protein interactions are shown in grey, chemical–protein interactions in green, and interactions between chemicals in red; stronger associations are represented by thicker lines. Small nodes: protein of unknown 3D structure; large nodes: some 3D structure is known or predicted; colored nodes: query proteins and first shell of interactors; white nodes: second shell of interactors. The chemical groups and structures in the gray rectangles, such as carbon dioxide, oxygen, and HO-, suggest functional links and predictions for specific actions on with potentially acting protein targets and combined scores of predicted interactions presented by analysing the Experimental/Biochemical Data, Association in Curated Databases and Co-Mentioned in PubMed Abstracts, which illustrated the possibility of interaction between compounds and potential protein targets. Associations are meant to be specific and meaningful, i.e., Proteins jointly contribute to a shared function; this does not necessarily mean they are physically binding each other. Predicted models were constructed by STITCH, Swiss Target Prediction, and Herbal Ingredients’ Targets database.
Molecules 23 00940 g001
Molecules 23 00940 g002 550
Figure 2. Strong association actions of compound and predicted target network of Panax notoginseng (Burk) F. H. Chen. (A) represents re-center network or functional domain of compounds associated with BCL2-A1; (B) represents BCL2; (C) represents TP53; (D) represents NFKB1; BCL2-A1, BCL2, NF-kappa-B, and TP53 were predicted to have strong association actions of compound and predicted target network of Panax notoginseng (Burk) F. H. Chen, indicating that PNS may exert anti-depression and anti-anxiety effects through inflammatory regulation and anti-apoptotic pathway. Association action models were constructed by STITCH and PDB database.
Figure 2. Strong association actions of compound and predicted target network of Panax notoginseng (Burk) F. H. Chen. (A) represents re-center network or functional domain of compounds associated with BCL2-A1; (B) represents BCL2; (C) represents TP53; (D) represents NFKB1; BCL2-A1, BCL2, NF-kappa-B, and TP53 were predicted to have strong association actions of compound and predicted target network of Panax notoginseng (Burk) F. H. Chen, indicating that PNS may exert anti-depression and anti-anxiety effects through inflammatory regulation and anti-apoptotic pathway. Association action models were constructed by STITCH and PDB database.
Molecules 23 00940 g002
Table
Table 1. Phytochemicals and mechanisms with antidepressant effects in Panax notoginseng saponins (PNS).
Table 1. Phytochemicals and mechanisms with antidepressant effects in Panax notoginseng saponins (PNS).
NameMethodsModelsNeurobehavioral Effects and Mechanisms
PNS (58.6%)OFT; TST; FST; SPT [26,53]CMS-induced mice; CUMS-induced rats [26,53]↓ Immobility time in FST and TST; ↑ sucrose intake in sucrose preference test; ↑ level of animal activity; ↑ Expression of BDNF [40,60,68,69,70].
Purified PNSSPT; OFT [45,71]CUMS-induced SD rats [45,71]Regulate upstream neural signal transduction pathways: AC/cAMP/PKA, TrKB/MAPK/PSK and Ca2+/CaM/CaMK signaling pathway;
↓ Concentration of Ca2+ in nerve cells; ↑ release of neurotransmitter 5-HT, DA, and NE [45,71].
PNS and GTSFST; SPT [53,75,76,77,78].LPS-induced KM mice; CD-1 mice [53,75,76,77,78]↓ mRNA of IL-1β, IL-6, TNF-α, and IDO; ↓ Inflammation in the brain [53,75,76,77,78].
Ginsenoside Rg1OFT; FST; SPT [19,45]CMS and CUMS-induced depression Animal Model [19,45]↓ CMS-induced increasement of corticosterone levels in serum; ↑ CUMS-induced CREB phosphorylation in the amygdala of the brain [45]; ↑ expression of BDNF [33,43]; regulate hyperactivity of the HPA axis in depressed states; ↑neuronal status, neurons quantity and density of dendritic spines [19,45].
Ginsenoside Rg1FST; SPT [79]CMS and CUMS-induced depression animal model [80]↑ Expression of connexin and gap junction of astrocytes in the prefrontal cortex of the brain; ↑ dense ultrastructure; ↓ permeability and depression-like behaviors induced by CUS in rats [79].
Ginsenoside Rg1FST; SPT [10]Cerebral inflammatory model mice [10]↓ Recruitment of Ly6C (hi) monocytes in inflammatory brain model mice [10,16]; activate THP-1 monocytes; blocks the feedback-regulated release of CCL2 from astroglial cells; ↓ CCL2 signaling pathways: p38/MAPK and PI3K/Akt activities [10,81].
Ginsenoside Rg1TST; FST; SPT [15,67]CUMS-induced depression rats [67]↓ Contents of Glu and Asp in hippocampus, ↑ contents of GABA and Tau; ↓ depression-like Behavior in CUMS model rats [15,67]
Ginsenoside Rb1 and ginsenoside KTST; FST [42]CUMS-induced depression rats [42]↑ Expression of 5-HT2AR mRNA and activate of 5-HT2AR [42]; the antidepressant effects of Rb1 and the metabolite ginsenoside K may be antagonized by 5-HT2AR antagonists (Ritanerin), indicating that Rb1 has a similar 5-HT transmitter activation effect [68,82,83].
Ginsenoside Rg3 and ginsenoside Rh2OFT; SPT [19,53,74]LPS-induced mice [19,53,74] and CSDS-induced mice [74]↓ IL-6 and TNF-α in plasma and the expression of indoleamine 2,3-dioxygenase (IDO) in brain; ↓ turnover of tryptophan and 5-HT in hippocampal tissue; regulate secretory activities of microglia and transcription of NF-kappa-B in nuclear; ↑ expression of BNDF; ↓ depressive behavior or symptoms [53,74,84].
Ginsenoside Rg5OFT; FST; SPT [85]CSDS-induced mice [85]↓ Trk and AchE; ↑expression of BNDF [69,85].
Ginsenoside ReOFT; TST [44]CMS-induced rat model [44]Regulate the central adrenergic system; ↓ expression of TH in the locus coeruleus area; ↓ decrease of BDNF in the hippocampus, and regulates the secretion of corticosterone from the HPA axis [44].
GST, ginseng total saponin ; SPT, sucrose preference test; FST, forced swimming test; OFT, open field test; TST, tail suspension test; CMS, chronic mild stress; CUMS, chronic unpredictable mild stress; CREB, cAMP response element-binding protein; CSDS, chronic social defeat stress.
Table
Table 2. Phytochemicals and mechanisms with anxiolytic effects in Panax notoginseng saponins (PNS).
Table 2. Phytochemicals and mechanisms with anxiolytic effects in Panax notoginseng saponins (PNS).
NameMethodsModelsNeurobehavioral Effects and Mechanisms
PNSOFT; SPT [26,28]l-DOPA-induced mice [26,28]; 5-HTP-induced rats [89]↓ Basal [Ca2+]i levels; ↓ immobility time; ↑ levels of 5-HT, DA and NE [26,28,89].
Ginsenoside Rb1EPM test [44,91]SPS model and rat model of post-traumatic stress disorder [44,91]↓ Anxiety index;↑ Risk assessment; ↓ grooming behaviors in EPMT; ↑ total number of line crossings of an open field after SPS; ↓ SPS-induced decreasement in hypothalamic neuropeptide Y expression; ↑ in locus cerulean tyrosine hydroxylase expression; ↓ expression of BDNF [44,91].
Ginsenoside Rb1, Re; ginsenoside Rh1, PPDEPM test [27,40]Immobilization stress-induced ICR mice [27,40]↑ Time spent in open arms and open arm entries in EPM tests; ↓ Immobilization stress-induced serum levels of corticosterone and IL-6; ↓ anxiolytic effect via γ-aminobutyrate A (GABA A) receptor(s) [27,40].
Ginsenoside Rg3Two electrode voltage-clamp technique [86,92]Xenopus laevis frogs [86,92]↓ Anxiolytic effect via γ-aminobutyrate A (GABA A) receptor(s) [86,92].
Ginsenoside ReFST; EPM; AAT [44]Repeated immobilization stress-induced rats [44]↓ Stress-induced behavioral deficits in these behavioral tests; ↓ TH expression in LC; ↓ mRNA expression of BDNF in the hippocampus; modulate central noradrenergic system in rats [44].
Ginsenoside Rg3 and ginsenoside Rh2EPM test [27,84]Male ICR mice [27,84]↑ Time spent on the open arms and the number of open-arm entries; antagonize GABA/benzodiazepines [27,84].
Ginsenoside Rb1, Rg1, and RoEPM test [68,84]Male ICR albino mice [68,84]↑ Both the frequency and duration of open arm entries [68,84].
Pseudoginsenoside-F11Light-dark box test; FST [90]MA-induced behavioral and neurochemical toxicities in mice [90]↓ Anxiety-like behavior induced by methamphetamine (MA); ↓ MA-induced prolonged latency; ↓ the error counts; ↓ contents of DOPAC, HVA, and 5-HIAA in the brain of MA-treated mice; antagonize decreases of DA [90].
EPM, elevated plus-maze.
Table
Table 3. Active ingredients of Panax notoginseng saponins.
Table 3. Active ingredients of Panax notoginseng saponins.
No.NameStructure
PNS-1Ginsenoside Rg1 Molecules 23 00940 i001
PNS-2Ginsenoside Rg3 Molecules 23 00940 i002
PNS-3Ginsenoside Rg5 Molecules 23 00940 i003
PNS-4Ginsenoside Rb1 Molecules 23 00940 i004
PNS-5Ginsenoside Rb3 Molecules 23 00940 i005
PNS-6Ginsenoside Re Molecules 23 00940 i006
PNS-7Ginsenoside Rh1 Molecules 23 00940 i007
PNS-8Ginsenoside Rh2 Molecules 23 00940 i008
PNS-9Pseudoginsenoside-F11 Molecules 23 00940 i009
PNS-10Ginsenoside Ro Molecules 23 00940 i010
PNS-11Ginsenoside K Molecules 23 00940 i011
PNS-12Notoginsenoside R1 Molecules 23 00940 i012
Table
Table 4. Main predicted target information of Panax notoginseng (Burk) F. H. Chen.
Table 4. Main predicted target information of Panax notoginseng (Burk) F. H. Chen.
Node1Node2Node1 AccessionNode2 AccessionScore
APAF1BAK1ENSP00000448165ENSP000003538780.997
APAF1BCL2ENSP00000448165ENSP000003296230.999
APAF1BCL2A1ENSP00000448165ENSP000002679530.912
APAF1BIKENSP00000448165ENSP000002161150.932
APAF1JUNENSP00000448165ENSP000003602660.582
APAF1MAPK8ENSP00000448165ENSP000003534830.611
APAF1MCL1ENSP00000448165ENSP000003580220.95
APAF1NFKB1ENSP00000448165ENSP000002265740.608
APAF1TP53ENSP00000448165ENSP000002693050.996
BAK1APAF1ENSP00000353878ENSP000004481650.997
BAK1BBC3ENSP00000353878ENSP000004045030.414
BAK1BCL2ENSP00000353878ENSP000003296230.999
BAK1BCL2A1ENSP00000353878ENSP000002679530.987
BAK1BIKENSP00000353878ENSP000002161150.583
BAK1JUNENSP00000353878ENSP000003602660.852
BAK1JUNBENSP00000353878ENSP000003033150.658
BAK1JUNDENSP00000353878ENSP000002528180.671
BAK1MAPK8ENSP00000353878ENSP000003534830.83
BAK1MCL1ENSP00000353878ENSP000003580220.99

Share and Cite

MDPI and ACS Style

Xie, W.; Meng, X.; Zhai, Y.; Zhou, P.; Ye, T.; Wang, Z.; Sun, G.; Sun, X. Panax Notoginseng Saponins: A Review of Its Mechanisms of Antidepressant or Anxiolytic Effects and Network Analysis on Phytochemistry and Pharmacology. Molecules 2018, 23, 940. https://doi.org/10.3390/molecules23040940

AMA Style

Xie W, Meng X, Zhai Y, Zhou P, Ye T, Wang Z, Sun G, Sun X. Panax Notoginseng Saponins: A Review of Its Mechanisms of Antidepressant or Anxiolytic Effects and Network Analysis on Phytochemistry and Pharmacology. Molecules. 2018; 23(4):940. https://doi.org/10.3390/molecules23040940

Chicago/Turabian Style

Xie, Weijie, Xiangbao Meng, Yadong Zhai, Ping Zhou, Tianyuan Ye, Zhen Wang, Guibo Sun, and Xiaobo Sun. 2018. "Panax Notoginseng Saponins: A Review of Its Mechanisms of Antidepressant or Anxiolytic Effects and Network Analysis on Phytochemistry and Pharmacology" Molecules 23, no. 4: 940. https://doi.org/10.3390/molecules23040940

Article Metrics

Back to TopTop